GENE ONLINE|News &
Opinion
Blog

2026-02-08|

Study Finds Limited Evidence Linking Exercise to Changes in SASP Biomarkers in Older Adults

by GOAI
Share To

A recent systematic review and meta-analysis examined the relationship between exercise and its impact on SASP (senescence-associated secretory phenotype) biomarkers in older adults. Researchers focused on how physical activity may influence these biomarkers, which are associated with aging and age-related diseases. Despite growing interest in lifestyle interventions for improving health outcomes in seniors, the study found that the specific effects of exercise on SASP biomarkers remain largely unexplored.

The analysis, conducted by Sánchez-Romero et al., reviewed existing literature to assess whether exercise could modulate SASP biomarkers in aging populations. The findings highlighted a gap in current research, indicating limited evidence directly linking physical activity to changes in these biomarkers. While exercise is widely recognized for its general health benefits, its role in influencing molecular markers tied to cellular senescence has not been thoroughly investigated. The study underscores the need for further research to better understand this connection and its potential implications for healthy aging strategies.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 9, 2026

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
LATEST
Oragenics Submits Annual Report Highlighting Fiscal Year 2025 Financials and Research Updates
2026-03-17
SurgePays Launches Nationwide Campaign to Promote LinkUp Mobile Service
2026-03-17
Tempus and Blood Cancer United Collaborate to Build Extensive Pediatric AML Data Registry
2026-03-17
John Choe Appointed Western Sales Director at Buzz Bomb Caffeine Company
2026-03-17
Two RXO Leaders Earn Fourth Consecutive Recognition in Supply Chain Pros to Know Awards
2026-03-17
Pfizer Reports Phase 2 Trial Success for Atirmociclib in Second-Line Metastatic Breast Cancer Treatment
2026-03-17
Merck to Present Long-Term Efficacy Data on GARDASIL9 and GARDASIL at EUROGIN 2026
2026-03-17
Scroll to Top